Abcam, ab257449, Human GLA (Galactosidase alpha) knockout HeLa cell lysate

Size: 1Kit
GLA KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-GLA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Alpha-galactosidase also known as alpha-D-galactosidase or A-galactosidase is an enzyme that catalyzes the hydrolysis of terminal alpha-galactosyl moieties from glycolipids and glycoproteins. It has a molecular mass of approximately 50000 Daltons. This enzyme is expressed in various tissues including the liver heart and kidneys. It functions by efficiently removing alpha-galactose residues from target molecules a process important for maintaining cellular function.
Biological function summary
The role of alpha-galactosidase involves the breakdown of complex carbohydrates particularly those containing alpha-galactosidic bonds. It does not operate as part of a complex but rather functions independently to cleave these specific bonds in glycolipids and glycoproteins. This activity is critical for degrading langerin and other gangliosides preventing the accumulation of these molecules in the lysosomes. By continuously performing this function alpha-galactosidase maintains glycosphingolipid homeostasis ensuring efficient cellular metabolism.
Pathways
The involvement of alpha-galactosidase in metabolic and lysosomal catabolic pathways is significant. One critical pathway is the glycolipid metabolism pathway where it acts alongside related enzymes such as beta-galactosidase. It also participates in the lysosomal degradation pathway working in conjunction with other lysosomal enzymes to prevent substrate buildup. The interaction with enzymes like lysosomal hydrolases ensures the proper breakdown of complex molecules into simpler ones that cells can utilize or excrete.
Defects in the alpha-galactosidase enzyme lead to the lysosomal storage disorder known as Fabry disease. This genetic disorder causes the accumulation of globotriaosylceramide due to deficient alpha-galactosidase activity. Another disorder associated with malfunctioning alpha-galactosidase is cardiac complications due to tissue storage of glycolipids. In both cases the lack of enzyme activity disrupts cellular and tissue functions linking alpha-galactosidase to clinical symptoms seen in these disorders.